Dr. Ehrich joined Expansion Therapeutics in 2018 as Chief Medical Officer. Dr. Ehrich has spent over 25 years in drug development including the last eighteen years at Alkermes, plc, as Executive Vice President, R&D and Chief Medical Officer. While at Alkermes, he directed the development and successful FDA registration of VIVITROL and ARISTADA and partnered development of RISPERDAL CONSTA and BYDUREON. He established a drug discovery effort at Alkermes which has yielded a broad portfolio of proprietary drug development candidates in psychiatry, neurology, and immuno-oncology. Dr. Ehrich is currently a Venture Partner with 5AM Ventures and serves on the Scientific Advisory Boards of Praxis Precision Medicines, Aileron and Heptares and is a Strategic Advisor to Verge Genomics. Prior to Alkermes, Dr. Ehrich spent seven years at Merck & Co, Inc. working in clinical pharmacology and clinical development.
Dr. Ehrich received a B.A. degree from Princeton University and was a predoctoral fellow in molecular genetics at the European Molecular Biology Laboratory in Heidelberg, Germany. Following an M.D. degree at Columbia University, he completed a residency in internal medicine, subspecialty training in rheumatology, and a postdoctoral fellowship in immunology at Stanford University.